EGFR and non-small cell lung carcinoma: Combination use of EGFR-TKIs and BH3-mimetic compound ABT-737 upregulates BIM and overcomes erlotinib resistance in NSCLC cells expressing EGFR-mutant and harboring the BIM deletion polymorphism